Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
- PMID: 18065961
- DOI: 10.1038/modpathol.3800981
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
Abstract
TMPRSS2-ERG gene fusion leading to the androgenic induction of the ERG proto-oncogene expression is a highly prevalent oncogenic alteration in prostate tumor cells. Prostate cancer is a multi-focal disease, and the origins as well as biological contribution of multiple cancer foci remain unclear with respect to prostate cancer onset or progression. To assess the role of TMPRSS2-ERG alteration in prostate cancer onset and/or progression, we have evaluated the status of fusion transcripts in benign glands, prostatic intraepithelial neoplasia (PIN) and multiple cancer foci of each prostate. Quantitative expression of TMPRSS2-ERG fusion type A and C transcripts was analyzed in benign, tumor and PIN areas, selected from whole-mount radical prostatectomy slides. TMPRSS2-ERG expression was correlated with clinicopathological features. Overall, 30 of 45 (67%) patients exhibited TMPRSS2-ERG fusion transcripts in at least one tumor focus. Of 80 tumor foci analyzed, 39 had TMPRSS2-ERG fusion (type A only: 30, type C only: 2, both types A and C: 7), with predominant detection of the TMPRSS2-ERG fusion type A (27/30, 90%) in the index tumors. Of 14 PIN lesions, 2 were positive for type A fusion. Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer. However, heterogeneity of the TMPRSS2-ERG detection in the context of multiple cancer foci and its frequency in PIN also support the role of other genomic alterations in the origins of prostate cancer.
Similar articles
-
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6. Mod Pathol. 2010. PMID: 20693979
-
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194. Clin Cancer Res. 2008. PMID: 18519767 Free PMC article.
-
Role of the TMPRSS2-ERG gene fusion in prostate cancer.Neoplasia. 2008 Feb;10(2):177-88. doi: 10.1593/neo.07822. Neoplasia. 2008. PMID: 18283340 Free PMC article.
-
Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
-
Cellular and molecular pathology of prostate cancer precursors.Scand J Urol Nephrol Suppl. 2000;(205):19-43. doi: 10.1080/003655900750169284. Scand J Urol Nephrol Suppl. 2000. PMID: 11144897 Review.
Cited by
-
ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.Hum Pathol. 2016 Sep;55:117-25. doi: 10.1016/j.humpath.2016.04.017. Epub 2016 May 14. Hum Pathol. 2016. PMID: 27189342 Free PMC article.
-
MYC and Prostate Cancer.Genes Cancer. 2010 Jun;1(6):617-28. doi: 10.1177/1947601910379132. Genes Cancer. 2010. PMID: 21779461 Free PMC article.
-
Markers for detection of prostate cancer.Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125. Cancers (Basel). 2010. PMID: 24281110 Free PMC article.
-
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.Adv Anat Pathol. 2008 Nov;15(6):319-31. doi: 10.1097/PAP.0b013e31818a5c19. Adv Anat Pathol. 2008. PMID: 18948763 Free PMC article. Review.
-
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.Am J Clin Pathol. 2012 Nov;138(5):685-96. doi: 10.1309/AJCPU7PPWUPYG8OH. Am J Clin Pathol. 2012. PMID: 23086769 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical